10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics

CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics

Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) is a complex systemic syndrome triggered by progressive nephron loss and disrupted mineral homeostasis. As glomerular filtration rate (GFR) declines below 60 mL/min/1.73 m², the kidney's capacity to excrete phosphate and synthesize active vitamin D diminishes, initiating a cascade of endocrine maladaptations. The modern clinical definition established by Kidney Disease: Improving Global Outcomes (KDIGO) categorizes CKD-MBD not merely as bone pathology, but as an interrelated clinical triad comprising biochemical abnormalities, skeletal remodeling disorders, and cardiovascular or soft-tissue calcification.

---

The CKD-MBD Pathophysiologic Triad

The clinical management of CKD-MBD requires a comprehensive understanding of the three interconnected components that drive patient morbidity and mortality:

                     ┌────────────────────────────────────────────────────────┐
                     │                  The CKD-MBD Triad                     │
                     └────────────────────────────────────────────────────────┘
                                                  │
         ┌────────────────────────────────────────┼───────────────────────────────────────┐
         ▼                                        ▼                                       ▼
┌────────────────────────────────┐ ┌────────────────────────────────┐ ┌────────────────────────────────┐
│    Biochemical Derangements    │ │      Renal Osteodystrophy      │ │ Extraskeletal Calcification    │
├────────────────────────────────┤ ├────────────────────────────────┤ ├────────────────────────────────┤
│ • Hyperphosphatemia            │ │ • Osteitis Fibrosa Cystica     │ │ • Coronary Artery Calcification│
│ • Hypocalcemia / Hypercalcemia │ │   (High turnover, high PTH)    │ │ • Medial Arterial Sclerosis    │
│ • Elevated Intact PTH (sHPT)   │ │ • Adynamic Bone Disease        │ │   (Mönckeberg sclerosis)       │
│ • Elevated FGF-23              │ │   (Low turnover, oversuppr.)   │ │ • Calcific Uremic Arteriolopathy│
│ • Deficient 1,25(OH)2D         │ │ • Osteomalacia                 │ │   (Calciphylaxis / CUA)        │
│ • Altered Klotho Expression    │ │   (Unmineralized osteoid)      │ │ • Cardiac Valvular Calcification│
└────────────────────────────────┘ └────────────────────────────────┘ └────────────────────────────────┘

1. Endocrine and Biochemical Cascade

When functional nephrons decline, renal clearance of inorganic phosphate decreases, causing transient intracellular and systemic phosphate retention. In response, osteocytes and osteoblasts upregulate Fibroblast Growth Factor 23 (FGF-23), a phosphaturic hormone that binds to the Klotho-FGFR1 coreceptor complex in the renal proximal tubule to promote urinary phosphate excretion.

However, markedly elevated FGF-23 directly downregulates renal 1α-hydroxylase (CYP27B1) and upregulates the catabolic 24-hydroxylase (CYP24A1), resulting in severe deficiency of 1,25-dihydroxyvitamin D [calcitriol]. Calcitriol deficiency impairs intestinal calcium absorption, producing hypocalcemia. Hypocalcemia, hyperphosphatemia, calcitriol deficiency, and skeletal resistance to parathyroid hormone collectively stimulate parathyroid chief cells. Over time, parathyroid Calcium-Sensing Receptors (CaSR) and Vitamin D Receptors (VDR) downregulate, culminating in autonomous parathyroid cell hyperplasia and Secondary Hyperparathyroidism (sHPT).

2. Renal Osteodystrophy Spectrum

Renal osteodystrophy describes the altered bone morphology, turnover, volume, and mineralization accompanying CKD:

• High-Turnover Bone Disease (Osteitis Fibrosa Cystica): Driven by sustained, severe PTH elevations. Osteoclasts and osteoblasts are hyperactive, producing rapid but disorganized woven bone deposition accompanied by peritrabecular marrow fibrosis. Bone fragility and fracture risks are markedly increased.
• Low-Turnover Bone Disease (Adynamic Bone Disease): Characterized by profound suppression of bone turnover, cellular quiescent surfaces, and minimal osteoblastic/osteoclastic activity. Often iatrogenically induced by oversuppression of PTH via excessive calcium-based phosphate binders, active vitamin D sterols, or calcimimetics. Crucially, adynamic bone loses its buffering capacity to absorb circulating calcium and phosphate postprandially, shunting excess minerals directly into vascular beds.
• Osteomalacia: Defined by an accumulation of unmineralized osteoid matrix resulting from delayed mineralization. Historically caused by aluminum toxicity from aluminum-containing binders or dialysate contamination; today primarily seen with severe nutritional vitamin D deficiency or hypophosphatemic states.

3. Extraskeletal and Vascular Calcification

Elevated serum phosphorus and calcium drive vascular smooth muscle cells (VSMCs) to undergo phenotypic transdifferentiation into osteoblast-like cells through the PiT-1 sodium-dependent phosphate cotransporter. These transdifferentiated VSMCs downregulate calcification inhibitors (such as matrix Gla protein and fetuin-A) and upregulate osteogenic transcription factors (Runx2/Cbfa1, osteocalcin, and alkaline phosphatase), producing active hydroxyapatite crystal deposition within arterial walls.

• Medial Arterial Calcification (Mönckeberg Sclerosis): Mineralization of the internal elastic lamina and tunica media of large and medium conduits. This leads to vessel wall stiffening, widened pulse pressure, accelerated pulse wave velocity, left ventricular hypertrophy (LVH), and fatal cardiovascular events.
• Calcific Uremic Arteriolopathy (CUA / Calciphylaxis): A life-threatening syndrome characterized by calcification, subintimal endovascular fibrosis, and microthrombosis of subcutaneous arterioles and dermal microvasculature. It manifests as exquisitely painful, violaceous, ischemic skin lesions that progress to non-healing, necrotic, escharotic ulcers, predominantly in adipose-rich areas (abdomen, thighs, breasts). One-year mortality exceeds 50%, primarily from ulcer superinfection and systemic sepsis. Key risk factors include female sex, obesity, high calcium-phosphorus product, hyperphosphatemia, and warfarin therapy (which inhibits vitamin K-dependent carboxylation of matrix Gla protein).

---

Comparative Pharmacology of Phosphorus Binders

Phosphate binders reduce gastrointestinal absorption of dietary phosphorus by forming insoluble, non-absorbable precipitates within the stomach and intestinal lumen that are subsequently eliminated in feces. Because phosphate binders act locally on ingested food, all phosphate binders must be taken with meals and snacks. Since January 1, 2025, oral binders for Medicare dialysis patients are paid through the ESRD PPS bundle and supplied by the dialysis facility. If taken on an empty stomach, binders fail to bind dietary phosphate and, in the case of calcium salts, act merely as systemic calcium supplements.

Calcium Limits: What Each Guideline Says

Guidelines limit calcium loading to prevent positive calcium balance, but they express it differently:

1. KDOQI 2003 (bone metabolism): elemental calcium from binders no more than 1,500 mg/day and total intake no more than 2,000 mg/day. These numbers are still widely taught.
2. KDIGO 2017: restrict the dose of calcium-based binders in adults with CKD G3a–G5D (2B), without a fixed number, and avoid hypercalcemia.
3. KDOQI 2020: in CKD 3–4 not taking active vitamin D, total elemental calcium of 800–1,000 mg/day from diet, supplements and binders (2B); in CKD 5D, adjust calcium intake with attention to vitamin D analogs and calcimimetics (OPINION).
4. Avoid calcium-based binders entirely in patients with:
   • Persistent or recurrent hypercalcemia (corrected serum calcium >10.2 mg/dL).
   • Documented adynamic bone disease (intact PTH persistently <100 pg/mL).
   • Severe, progressive vascular or soft-tissue calcification (confirmed on coronary artery CT or plain radiographs).
   • Calcific uremic arteriolopathy (calciphylaxis).

---

Vitamin D Sterols & Selective Receptor Activators

Therapeutic vitamin D management in CKD requires differentiating nutritional vitamin D repletion from active vitamin D receptor activation (VDRA):

                                    Vitamin D Metabolic Pathways in CKD
                                    
  Nutritional Inactive Precursors              Hepatic Hydroxylation                 Renal Hydroxylation (Lost in CKD)
  ┌─────────────────────────────┐             ┌─────────────────────┐             ┌──────────────────────────────────┐
  │ Ergocalciferol (Vitamin D2) │ ──────────> │ 25-hydroxyvitamin D │ ──────────> │ 1,25-dihydroxyvitamin D3         │
  │ Cholecalciferol (Vitamin D3)│   (Liver)   │ [Calcidiol, 25(OH)D]│   (Kidney   │ [Calcitriol, Active Vitamin D]   │
  └─────────────────────────────┘             └─────────────────────┘   CYP27B1)  └──────────────────────────────────┘
                                                         ▲                                       │
                                                         │ Hepatic 25-Hydroxylation              ▼ Direct VDR Activation
                                              ┌───────────────────────┐           ┌──────────────────────────────────┐
                                              │    Doxercalciferol    │           │    Calcitriol / Paricalcitol     │
                                              │ (1α-hydroxyvitamin D2)│           │ (Active Sterols & Selective VDRA)│
                                              └───────────────────────┘           └──────────────────────────────────┘

1. Nutritional Vitamin D (Ergocalciferol and Cholecalciferol)

In patients with CKD Stages G1–G5 and dialysis, 25-hydroxyvitamin D [25(OH)D] may be measured and repeated based on baseline values and treatment (KDIGO 2017). Thresholds vary: the KDOQI 2003 bone guideline called levels below 15 ng/mL deficient and 16–30 ng/mL insufficient, and KDIGO 2017 advises correcting deficiency and insufficiency as for the general population. KDOQI 2020 (statement 5.3.1, grade 2C) suggests cholecalciferol or ergocalciferol to correct 25(OH)D deficiency or insufficiency. Repletion protocols often use 50,000 IU weekly or every other week for 8 to 12 weeks, then maintenance dosing (e.g., 1,000 to 2,000 IU daily). Nutritional vitamin D supports extrarenal 1α-hydroxylase activity in immune cells and peripheral tissues without inducing significant hypercalcemia.

2. Active Vitamin D Sterols & Receptor Activators

KDIGO 2017 suggests not using calcitriol or vitamin D analogs routinely in CKD G3a–G5 not on dialysis, reserving them for severe and progressive hyperparathyroidism in G4–G5; in G5D, calcimimetics, calcitriol, vitamin D analogs or a combination may be used to lower PTH. The active agents directly suppress parathyroid hormone gene transcription:

• Calcitriol (1,25(OH)2D3; Rocaltrol, Calcijex): Non-selective natural ligand. Highly potent PTH suppression; however, it strongly upregulates intestinal TRPV6 calcium channels and calbindin-D9k, significantly increasing intestinal absorption of both calcium and phosphorus. High risk of hypercalcemia, hyperphosphatemia, and accelerated vascular calcification.
• Paricalcitol (19-nor-1,25(OH)2D2; Zemplar): Synthetic selective VDRA. Chemically modified by removing carbon 19 and altering the vitamin D2 side chain. Exhibits selective affinity for parathyroid VDRs with markedly reduced activity on intestinal and osteocytic VDRs. Suppresses PTH with significantly lower hypercalcemic and hyperphosphatemic liability than calcitriol.
• Doxercalciferol (1α-hydroxyvitamin D2; Hectorol): Synthetic prodrug that requires hepatic 25-hydroxylation to form active 1,25-dihydroxyvitamin D2. Exhibits therapeutic efficacy similar to paricalcitol.

Practice Guideline Monitoring Rule

Active vitamin D sterols and VDRAs must be withheld or downwardly titrated if:

• Corrected serum calcium exceeds 10.2 mg/dL.
• Serum phosphorus exceeds 5.5 mg/dL.
• Intact PTH drops below 100–150 pg/mL (to prevent adynamic bone disease).

---

Calcimimetics: Calcium-Sensing Receptor Modulators

Calcimimetics represent a transformative class of agents that directly suppress parathyroid hormone secretion without introducing exogenous calcium or phosphorus into the circulation.

Mechanism of Action

Calcimimetics are allosteric activators of the Calcium-Sensing Receptor (CaSR), a G-protein-coupled receptor located on the surface of parathyroid chief cells. By binding to the transmembrane domain of the CaSR, calcimimetics induce a conformational change that increases the receptor's sensitivity to ambient extracellular ionized calcium. This shifts the concentration-response curve for calcium-regulated PTH suppression to the left, tricking the parathyroid gland into sensing higher ambient calcium levels. Consequently, parathyroid chief cells immediately suppress PTH secretion and transcription. Because PTH suppression reduces osteoclastic bone resorption, calcimimetics lower serum calcium, serum phosphorus, and intact PTH simultaneously.

1. Oral Cinacalcet (Sensipar)

• Starting Dose: 30 mg orally once daily. Titrated every 2 to 4 weeks (up to a maximum of 180 mg/day) targeting intact PTH within the KDIGO target range (approximately 2 to 9 times the upper limit of normal, or ~150 to 600 pg/mL in hemodialysis).
• Administration Rule: Must be taken with food or immediately after a meal, which increases systemic bioavailability by 50% to 80%.
• Adverse Effects: Gastrointestinal distress is common, with nausea and vomiting occurring in ~30% of patients. Hypocalcemia develops in 5% to 15% of patients.
• Critical Safety Rule: Never initiate or titrate cinacalcet if corrected serum calcium is below 8.4 mg/dL.

2. Intravenous Etelcalcetide (Parsabiv)

• Chemical Structure: A synthetic, linear D-amino acid octapeptide that binds covalently to the extracellular domain of the CaSR via a disulfide bond with cysteine residues.
• Administration: Administered as an IV bolus into the venous return line of the hemodialysis blood circuit at the end of each hemodialysis treatment (3 times weekly). Initial dose is 5 mg (or 2.5 mg) three times weekly.
• Clinical Advantage: Completely eliminates medication non-adherence associated with high oral pill burdens.
• Adverse Effects & Safety Monitoring: Causes more potent calcium reductions than oral cinacalcet. Can induce asymptomatic or symptomatic hypocalcemia (paresthesias, muscle spasms, tetany, seizures) and QT interval prolongation on ECG. Corrected serum calcium must be checked prior to initiation, 1 week after starting or titrating, and monthly thereafter. Withhold etelcalcetide if corrected calcium drops below 7.5 mg/dL or if symptoms of hypocalcemia occur.